During the past decade, Wilmer Eye Institute conducted 66 clinical trials. In the 10-year time frame, 66 clinical trials started and 42 clinical trials were completed, i.e. on average, 63.6% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 23 clinical trials were completed. i.e. 82.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wilmer Eye Institute" #1 sponsor was "Johns Hopkins University" with 40 trials, followed by "Jaeb Center for Health Research" with 29 trials sponsored, "Hoffmann-La Roche" with 11 trials sponsored, "Lux Biosciences, Inc." with 5 trials sponsored and "Allergan" with 5 trials sponsored. Other sponsors include 38 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wilmer Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 30 trials as a collaborator, "Genentech, Inc." with 7 trials as a collaborator, "Allergan" with 6 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 4 trials as a collaborator and "Regeneron Pharmaceuticals" with 4 trials as a collaborator. Other collaborators include 63 different institutions and companies that were collaborators in the rest 65 trials.

According to Clinical.Site data, the most researched conditions in "Wilmer Eye Institute" are "Diabetic Macular Edema" (20 trials), "Amblyopia" (10 trials), "Retinitis Pigmentosa" (10 trials), "Diabetic Retinopathy" (8 trials) and "Neovascular Age-related Macular Degeneration" (6 trials). Many other conditions were trialed in "Wilmer Eye Institute" in a lesser frequency.

Most popular intervention types in "Wilmer Eye Institute" are "Drug" (87 trials), "Other" (20 trials), "Device" (15 trials), "Procedure" (15 trials) and "Behavioral" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Faricimab" (7 trials), "Ranibizumab" (7 trials), "Sham Procedure" (5 trials) and "Aflibercept" (3 trials). Other intervention names were less common.

The vast majority of trials in "Wilmer Eye Institute" are 130 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Wilmer Eye Institute". 3 are not yet recruiting, 14 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 81 completed trials in Wilmer Eye Institute, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Wilmer Eye Institute, 18 "Phase 1" clinical trials were conducted, 33 "Phase 2" clinical trials and 45 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 7 trials, and there were also 16 trials that are defined as “Not Applicable".